Olson S. C. auteur aut IRD Ngo-Giang-Huong Nicole auteur aut IRD Beck I. auteur aut IRD Deng W. J. auteur aut IRD Britto P. auteur aut IRD Shapiro D. E. auteur aut IRD Bumgarner R. E. auteur aut IRD Mullins J. I. auteur aut IRD Van Dyke R. B. auteur aut IRD Jourdain Gonzague auteur aut IRD Frenkel L. M. auteur aut IRD text journalArticle eng text/pdf born digital access To prevent mother-to-child-transmission of HIV-1, the 2010 WHO guidelines recommended prenatal zidovudine (ZDV) monotherapy (option A). To determine if ZDV monotherapy selects for HIV resistance in antiretroviral-naive women during pregnancy, specimens from 50 individuals were examined using pyrosequencing. ZDV-resistance mutations were detected at delivery in seven women (14%, 95% confidence interval 6.6-26.5%). These data raise the question whether women administered ZDV monotherapy for prevention of mother-to-child-transmission could have higher risk of virologic failure when later started on combination antiretroviral therapy, as has been demonstrated following single-dose nevirapine prophylaxis. specialized HIV-1 mother-to-child-transmission prophylaxis pyrosequencing resistance zidovudine THAILANDE 052 050 29 12 1467-1471 2015 0269-9370 https://www.documentation.ird.fr/hor/fdi:010065442 10.1097/qad.0000000000000737 0269-9370 [F B010065442] https://www.documentation.ird.fr/hor/fdi:010065442 https://www.documentation.ird.fr/intranet/publi/2015/12/010065442.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2016-01-14 2017-08-23 fdi:010065442 fre